Sinotherapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
319
- Stock Symbol
-
688247
- Share Price
-
$1.11
- (As of Wednesday Closing)
Sinotherapeutics General Information
Description
Sinotherapeutics Inc is engaged in the research and development, production, and sales of generic drugs and CRO services.
Contact Information
Website
www.sinotherapeutics.comCorporate Office
- Room 207, Building 1, Greenland Colorful Plaza
- Pudong New Area
- Shanghai
- China
Corporate Office
- Room 207, Building 1, Greenland Colorful Plaza
- Pudong New Area
- Shanghai
- China
Sinotherapeutics Stock Performance
As of 18-Nov-2026, Sinotherapeutics’s stock price is $1.11. Its current market cap is $505M with 453M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.11 | $1.13 | $1.03 - $1.68 | $505M | 453M | 5.95M |
Sinotherapeutics Financials Summary
As of 30-Sep-2026, Sinotherapeutics has a trailing 12-month revenue of $57.7M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 560,962 | 519,084 | 522,320 | 589,951 |
| Revenue | 57,696 | 62,098 | 71,301 | 42,385 |
| EBITDA | 2,322 | 11,113 | 22,658 | 11,763 |
| Net Income | 2,626 | 6,603 | 17,797 | 8,633 |
| Total Assets | 222,408 | 205,540 | 199,080 | 192,086 |
| Total Debt | 6 | 3 | 1 | 12 |
Sinotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sinotherapeutics Patents
Sinotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025214247-A1 | Enzalutamide pharmaceutical composition, preparation method therefor, and use thereof | Pending | 07-Apr-2024 | ||
| WO-2025195452-A1 | Isavuconazole pharmaceutical composition and preparation method therefor | Pending | 21-Mar-2024 | ||
| US-20250000801-A1 | Darolutamide pharmaceutical composition, preparation method therefor and use thereof | Pending | 26-Nov-2021 | ||
| WO-2023093640-A1 | Darolutamide pharmaceutical composition, preparation method therefor and use thereof | Inactive | 26-Nov-2021 | ||
| US-12661324-B2 | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof | Active | 25-Nov-2020 | A61K9/2866 |
Sinotherapeutics Signals
Sinotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Sinotherapeutics FAQs
-
When was Sinotherapeutics founded?
Sinotherapeutics was founded in 2012.
-
Where is Sinotherapeutics headquartered?
Sinotherapeutics is headquartered in Shanghai, China.
-
What is the size of Sinotherapeutics?
Sinotherapeutics has 319 total employees.
-
What industry is Sinotherapeutics in?
Sinotherapeutics’s primary industry is Drug Discovery.
-
Is Sinotherapeutics a private or public company?
Sinotherapeutics is a Public company.
-
What is Sinotherapeutics’s stock symbol?
The ticker symbol for Sinotherapeutics is 688247.
-
What is the current stock price of Sinotherapeutics?
As of 18-Nov-2026 the stock price of Sinotherapeutics is $1.11.
-
What is the current market cap of Sinotherapeutics?
The current market capitalization of Sinotherapeutics is $505M.
-
What is Sinotherapeutics’s current revenue?
The trailing twelve month revenue for Sinotherapeutics is $57.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process